Nuo Therapeutics, Inc.
AURX · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.61 | 2.15 | -0.38 | 2.00 |
| FCF Yield | -0.73% | 0.37% | -0.41% | -0.75% |
| EV / EBITDA | -178.81 | -114.59 | -75.52 | -139.74 |
| Quality | ||||
| ROIC | -72.49% | -150.91% | -17,758.51% | -92.82% |
| Gross Margin | 60.59% | 77.24% | 75.02% | 78.12% |
| Cash Conversion Ratio | 1.31 | -0.40 | -0.00 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | 75.21% | 88.43% | 110.42% | 129.97% |
| Free Cash Flow Growth | -371.01% | 214.31% | 53.51% | 23.15% |
| Safety | ||||
| Net Debt / EBITDA | 0.74 | 0.30 | -0.12 | 0.26 |
| Interest Coverage | -1,320.64 | 0.00 | -467.18 | -5,880.69 |
| Efficiency | ||||
| Inventory Turnover | 2.02 | 0.96 | 1.22 | 0.57 |
| Cash Conversion Cycle | -7.30 | -41.88 | -367.25 | -15.03 |